drugset / Trial / NCT07704684

Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine

NCT07704684

Phase 3 Completed 376 enrolled Shenzhen Salubris Pharmaceuticals Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with Amlodipine (5mg).

Timeline

Start
2023-06-28
Primary completion
2025-08-26
Completion
2025-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg
Subject Sacubitril Small molecule 240 mg